Kidney Cancer

Patients may require specific diagnostic, surveillance, and therapeutic management.

The FDA is scheduled to decide on the application for adjuvant pembrolizumab in renal cell carcinoma on or before December 10, 2021.

Ventana MMR RxDx Panel is a qualitative immunohistochemistry test that assesses a panel of MMR proteins to help guide clinicians in their treatment decisions.

Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma.

The FDA has approved belzutifan (Welireg) for adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma.

The FDA has approved pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced renal cell carcinoma.

Inhibiting the HDL cholesterol receptor SCARB1 can kill and stop the proliferation of clear cell renal cell carcinoma cells.

The application for adjuvant pembrolizumab in renal cell carcinoma is supported by data from the phase 3 KEYNOTE-564 trial, which were presented at the 2021 ASCO Annual Meeting.

The combination achieved a high objective response rate among patients previously treated with immune checkpoint inhibitors.

“To our knowledge, this study represents the first attempt to assess the associations between demographic factors and receipt of non–guideline-based treatment among patients with kidney cancer,” the authors of the study wrote.

Bradley McGregor, MD, explains how despite the groundbreaking immunotherapy-based advances in metastatic renal cell carcinoma, unmet medical needs remain.

Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.

Neoadjuvant stereotactic ablative radiation followed by radical nephrectomy and thrombectomy was safe and showed signs of positive clinical activity in patients with renal cell carcinoma and inferior vena cava tumor thrombus.

The guideline was initially published in 2013 and was last amended in 2017.

"Certainly, telemedicine is not a replacement for in-person encounters for all urologic conditions, but rather another tool in our armamentarium," writes Adele M. Caruso, DNP, CRNP, FAANP.

Overall survival was similar between patients selecting primary intervention or active surveillance.

Frontline immune checkpoint inhibitor therapy may improve overall survival in this setting.

Around the Practice: High-Risk Renal Cell Carcinoma

"Brain imaging is routinely obtained for kidney cancer patients with symptoms that suggest CNS metastases, but none of the patients with brain metastases included here were symptomatic," said Martin H. Voss, MD.

Substudy 03B is enrolling patients with disease progression after treatment with PD-1/PD-L1 inhibitors and VEGF-tyrosine kinase inhibitors.

The phase 3 KEYNOTE-564 trial remains ongoing to evaluate the key secondary end point of overall survival.

This recommendation is key for urologists to be aware of, in particular, because of the role of the multidisciplinary approach to renal cell carcinoma care, according to Eric Jonasch, MD.

Primo Lara, Jr, MD, highlights the multitude of available treatments in frontline renal cell carcinoma, and the need for individualized, multidisciplinary treatment in this setting.

The study is comparing the triplet regimen with nivolumab/ipilimumab alone as a frontline treatment for patients with advanced intermediate- or poor-risk renal cell carcinoma.

The approval was based on data from the pivotal phase 3 CheckMate-9ER trial.

Dr. Primo Lara, Jr., executive associate dean for Cancer Programs, School of Medicine, at UC Davis Comprehensive Cancer Center, highlights the need for personalized medicine using multidisciplinary care for patients with renal cell carcinoma.

Tivozanib is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.

Michael E. Hurwitz, MD, PhD, discusses how immune checkpoint inhibitors have transformed the first-line setting in advanced renal cell carcinoma.

Tivozanib is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.

The FDA is scheduled to decide on the new drug application by September 15, 2021.